Overview

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab
Erlotinib Hydrochloride